✦ LIBER ✦

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

✍ Scribed by Jason E. Faris, Jamie Arnott, Hui Zheng, David P. Ryan, Thomas A. Abrams, Lawrence S. Blaszkowsky, Jeffrey W. Clark, Peter C. Enzinger, Aram F. Hezel, Kimmie Ng, Brian M. Wolpin, Eunice L. Kwak

Book ID: 113064556
Publisher: Springer US
Year: 2011
Tongue: English
Weight: 169 KB
Volume: 30
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-011-9708-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study with a daily regimen of

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

✍ Robert J. Amato; Jaroslaw Jac; Sarah Giessinger; Somyata Saxena; James P. Willis 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

A phase 2 study of KX2-391, an oral inhi

A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer

✍ Emmanuel S. Antonarakis, Elisabeth I. Heath… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 545 KB

Phase I–IIa study of BMS-690514, an EGFR

Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

✍ Soria, Jean-Charles; Baselga, José; Hanna, Nasser; Laurie, Scott A.; Bahleda, Ra 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 343 KB

Phase I Study of Rigosertib, an Inhibito

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

✍ Ma, W. W.; Messersmith, W. A.; Dy, G. K.; Weekes, C. D.; Whitworth, A.; Ren, C.; 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 440 KB

Phase I study evaluating the combination

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

✍ Gadgeel, Shirish M.; Lew, Danika L.; Synold, Timothy W.; LoRusso, Patricia; Chun 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 400 KB

358 A Multi-arm Phase 1 Dose Escalation

358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer

✍ Britten, C.; Wainberg, Z.; Tabernero, J.; Alsina Maqueda, M.; Leong, S.; Sessa, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 55 KB